Standalone and consolidated Audited Financial Results for the Half Year and Year to date ended March 31, 2026, along with Auditor''s Report thereon is attached herewith.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hamps Bio Limited reported audited standalone revenue of Rs. 884.86 lakhs for FY 2025-26, up from Rs. 681.91 lakhs in the previous year, representing approximately 30% revenue growth. However, the company swung to a net loss of Rs. 61.86 lakhs compared to a profit of Rs. 40.39 lakhs in FY 2024-25. The consolidated loss stands at Rs. 71.87 lakhs. During the year, the company acquired 100% stake in HSDL Innovative Private Limited (March 25, 2026) and issued bonus shares in 1:1 ratio. IPO proceeds of Rs. 622.20 lakhs were fully utilized for plant & machinery, brand visibility, and general corporate purposes. The statutory auditor M/s MGHVS & Associates issued an unmodified (clean) opinion on both standalone and consolidated results.
Despite strong revenue growth, the company posted losses which is a concern. The negative PAT and significant negative operating cash flows indicate operational challenges. The acquisition of the subsidiary and expansion into FMCG division may have impacted profitability. Shareholders should monitor if the company returns to profitability in upcoming quarters.